Last-Resort drug opens for severe hair loss patients
NCT ID NCT05522556
First seen Nov 18, 2025 · Last updated May 10, 2026 · Updated 20 times
Summary
This program offers early access to ritlecitinib, an experimental pill, for people with severe alopecia areata who have lost at least half of their scalp hair and have not improved with standard treatments. The goal is to provide a potential treatment option before the drug is fully approved. Participants must meet additional medical criteria set by their doctor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.